logo
Plus   Neg
Share
Email

Conatus Pharmaceuticals Inc. (CNAT) Is Climbing On Phase 2 Study Results

Conatus Pharmaceuticals Inc. (CNAT) announced after the bell Wednesday that its Phase 2 clinical trial of emricasan showed that the drug reduced hepatic venous pressure gradient in patients with liver cirrhosis and severe portal hypertension.

Conatus Pharmaceuticals gapped open higher Thursday and has taken out the highs of the morning in the last few minutes. Shares are now up 1.09 at $6.83 on above average volume. The stock has surged to a 5-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>